Prices for NutriStem, NutriCoat, and NutriFreez products will increase effective 1st August. Lock in the current price by getting your order by 31st July.
Blog
Subcutaneous Artery Assays Help Us to Understand Blood Pressure Regulation
Explore how subcutaneous artery assays enhance understanding of blood pressure regulation and aid in the development of safer, more effective cardiovascular drugs.
07 July 2025
Able Biott Single-use Bioreactors Enhance the Development of Disease Models and Cell Therapy
Discover how Able Biott single-use bioreactors enhance disease modeling and cell therapy development through scalable, efficient iPSC culture solutions.
03 July 2025
Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?
Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.
10 June 2025
New Therapeutic Targets: The Role of IL17-Related Genes in Precision Medicine
Discover how IL-17 related genes could revolutionize psoriasis treatment, offering new therapeutic targets and paving the way for precision medicine advancements.
09 June 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Come meet us on 4 September 2025 / Maryland, USA. Venue: Bethesda North Marriott Hotel & Conference Center
4 September
Come meet us on 6-8 October (in person) & 9-10 October (virtual) at Phoenix, AZ, USA. Venue: Arizona Biltmore
6-8 October (in person) & 9-10 October (virtual)
Come meet us 20-21 October 2025 / ACC Liverpool Exhibition Centre, UK / Booth #B07
21-22 October
Corporate News
Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration
Scottish Health Minister Neil Gray visits REPROCELL Japan to enhance life sciences collaboration, highlighting strong ties and innovative healthcare advancements between Scotland and Japan.
02 July 2025
REPROCELL Launches Immune Modulated iPSC Products
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
05 May 2025
REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc., reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy "Stemchymal®". REPROCELL holds the exclusive commercialization license agreement for Stemchymal in Japan for the treatment of Spinocerebellar Ataxia (SCA).
25 April 2025